Clinical Trials Logo

Nonadherence, Patient clinical trials

View clinical trials related to Nonadherence, Patient.

Filter by:
  • None
  • Page 1

NCT ID: NCT04071951 Active, not recruiting - Polypharmacy Clinical Trials

Pharmacist Intervention to Reduce Post-Hospitalization Utilization

Start date: December 23, 2019
Phase: N/A
Study type: Interventional

This is a randomized trial testing a peri- and post-discharge pharmacist-led medication management intervention on post-discharge utilization, including both readmissions and emergency department visits within 30 days of discharge. The intervention incorporates evidence addressing three main areas: medication reconciliation, medication adherence, and polypharmacy. This study uses a pragmatic trial randomized at the patient level and conducted in two large hospitals to achieve the following aims, each of which has been designed using the RE-AIM framework: Aim 1: To test the effect of PHARM-DC on post-discharge utilization among patients most at risk for post-discharge ADEs: recently discharged older adults taking >10 medications or >3 high-risk medications using a prospective, randomized, pragmatic multi-site study. Aim 2: To study barriers and facilitators of implementing PHARM-DC using a qualitative study. Aim 3: To analyze the costs of PHARM-DC, including the incremental cost per readmission averted and the net incremental cost from the health system perspective using a time-and-motion study and a cost-effectiveness analysis.

NCT ID: NCT03164902 Active, not recruiting - Clinical trials for Hepatitis C, Chronic

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

DASH
Start date: July 21, 2017
Phase: N/A
Study type: Interventional

This study evaluates the ability of digital medicines, Proteus Discover, to promote adherence and thus achieving a cure for hepatitis C in patients at high risk for not adhering to their hepatitis therapy. In this single-arm, prospective study, subjects at high risk for nonadherence will be prescribed hepatitis C therapy that will be co-encapsulated with ingestible sensors (creating the digital medicine) by a pharmacy. Both the subject and the providers will have access to the ingestion adherence.